174774-80-2

Upstream product

• 105191-14-8 5-Cyanbenzothiophen-2-carbonsaeure-ethylester 
• 25785-09-5 ethyl 5-nitro-2-benzo[b]thiophenecarboxylate 
• 25785-10-8 ethyl 5-amino-1-benzothiophene-2-carboxylate 
• 167843-57-4 tert-butyl 2-(4-aminophenoxy)acetate 
• 154650-76-7 5-cyanobenzo[b]thiophene-2-carboxylic acid 

Downstream Products

• 1026868-22-3 {4-[(5-methylsulfanylcarbonimidoyl-benzo[b]thiophene-2-carbonyl)-amino]-phenoxy}-acetic acid tert-butyl ester 
• 1026500-69-5 {4-[(5-mercaptocarbonimidoyl-benzo[b]thiophene-2-carbonyl)-amino]-phenoxy}-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives

A novel series of platelet receptor glycoprotein (Gp) IIb/IIIa antagonists with condensed heterocycles as their basic core was synthesized. In an in vitro assay, trans-4-(5-amidinobenzofuran-2- carboxamido)cyclohexyl]oxyacetic acid 17e and trans-3-[4-(5-

CARBOXYLIC ACID COMPOUND HAVING CONDENSED RING, SALT THEREOF AND PHARMACEUTICAL USE THEREOF

A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases